Suppr超能文献

程序性死亡配体 1 作为肿瘤进展和转移的调节剂。

Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis.

机构信息

Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, Greece.

Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.

出版信息

Int J Mol Sci. 2021 May 20;22(10):5383. doi: 10.3390/ijms22105383.

Abstract

Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has long been implicated in modeling antitumor immunity; PD-1/PD-L1 axis inhibitors exert their antitumor effects by relieving PD-L1-mediated suppression on tumor-infiltrating T lymphocytes. However, recent studies have unveiled a distinct, tumor-intrinsic, potential role for PD-L1. In this review, we focus on tumor-intrinsic PD-L1 signaling and delve into preclinical evidence linking PD-L1 protein expression with features of epithelial-to-mesenchymal transition program, cancer stemness and known oncogenic pathways. We further summarize data from studies supporting the prognostic significance of PD-L1 in different tumor types. We show that PD-L1 may indeed have oncogenic potential and act as a regulator of tumor progression and metastasis.

摘要

程序性细胞死亡蛋白 1(PD-1)/程序性死亡配体 1(PD-L1)免疫检查点长期以来一直被认为与抗肿瘤免疫有关;PD-1/PD-L1 轴抑制剂通过缓解 PD-L1 介导的对肿瘤浸润性 T 淋巴细胞的抑制作用发挥其抗肿瘤作用。然而,最近的研究揭示了 PD-L1 的一个独特的、内在的肿瘤内在的潜在作用。在这篇综述中,我们重点介绍内在的 PD-L1 信号,并深入研究将 PD-L1 蛋白表达与上皮-间充质转化程序、癌症干性和已知致癌途径的特征联系起来的临床前证据。我们进一步总结了支持 PD-L1 在不同肿瘤类型中具有预后意义的数据。我们表明,PD-L1 确实可能具有致癌潜力,并作为肿瘤进展和转移的调节剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9ba/8160779/d36c188bfe1e/ijms-22-05383-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验